Mon Sep 23 23:12:57 UTC 2024: ## Orgenesis to Undergo 1-for-10 Reverse Stock Split

**New York, NY – September 23, 2024** – Orgenesis Inc. (NASDAQ: ORGS), a biotech company specializing in cell and gene therapies, will execute a 1-for-10 reverse stock split before market open on Wednesday, September 25th. The move, announced on Monday, aims to increase the share price and potentially improve investor interest. The adjustment to shareholders’ holdings will be reflected after the closing bell on Tuesday, September 24th.

Orgenesis stock closed at $0.39 on Monday, having traded down $0.13 during the day. The company’s 52-week low stands at $0.25, while its 52-week high is $1.08.

The company’s recent financial performance showed a loss of $0.23 per share for the quarter ending August 8th, with revenue reaching $0.25 million.

Orgenesis operates through two segments: Octomera and Therapies. Their focus lies in developing a Point of Care (POCare) platform for cell-based therapies, leveraging closed and automated technology systems. The company collaborates with research institutions and hospitals through its POCare network.

Read More